Roche to present data across broad and impactful neuroscienc

maximally sustaining IL-6 suppression in a chronic disease like NMOSD and enabling subcutaneous dosing every four weeks. Positive Phase III results for ENSPRYNG, as both monotherapy and in... | March 25, 2022

Related Keywords

Japan , Kenya , United States , Canada , South Korea , Russia , Switzerland , America , American , Nathalie Meetz , Levi Garraway , Loren Kalm , Impact Of Administration Ocrelizumab , Sclerosis Care Center , Genentech , Drug Administration , Head Of Global Product Development , Risdiplam Clinical Trial Development Program , European Union , Roche Group , American Academy Of Neurology , European Medicines Agency , Roche Group Media Relations , American Academy , Annual Meeting , Chief Medical Officer , Global Product , Suboptimal Response , Prior Disease Modifying Therapies , Year Data , Year Interim Results , Term Suppression , Regional Volume Loss , Label Extension , Confirmed Disability Progressions Analyses , Open Label Extensions , Disease Progression , Post Hoc Analyses , Baseline Disease Characteristics , Hispanic Patients , Multiple Sclerosis Enrolled , Patterns Among Newly Diagnosed Patients , Multiple Sclerosis , Secondary Progressive Multiple Sclerosis , Assess Efficacy , Cognition Outcomes , Cellular Responses , Disease Modifying Therapies , Prospective Study , Home Infusion , Patient Reported Outcomes , Outcome Measures , Open Label Rollover Study , Subcutaneous Gantenerumab Long Term Safety , Clinical Trials , Early Alzheimer , Aging And Dementia , Clinical Aspects , Cognitive Impairments , Concept Study , Preliminary Clinical Validity , Remote Smartphone Based Self Assessments , Remote Assessments , Spinal Muscular , On Site Child , Preliminary Efficacy , Safety Data , Risdiplam Treated Infants , Child Neurology , Exploratory Efficacy Data , Spinal Muscular Atrophy , Receiving Treatment , Risdiplam Treatment , Pediatric Patients , Neuromyelitis Optica Spectrum , Term Safety , Neuromyelitis Optica Spectrum Disorder , Open Label Extension Periods , Autoimmune Neurology , Term Efficacy , Results From The Open Label Extension Periods , Open Label Study , Satralizumab Investigating Novel Imaging , Clinical Outcomes , Duchenne Muscular Dystrophy , Year Safety , Functional Outcomes , Trial Evaluating , Treating Patients , Orphan Drug Designation , Breakthrough Therapy Designation , Dow Jones Sustainability Indices , Chugai Pharmaceutical , Roche Holding Ag Stock Exchange , News , Information , Press Release , Maximally , Sustaining , Suppression , N , Hronic , Disease , Bike , Nmosd , End , Nabling , Subcutaneous , Closing , Very , Four , Positive , Hase , Wii , Results , Or , Us , Moth , Monotherapy , Nd Rog Ch0012032048 ,